Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

2.67USD
23 Oct 2017
Change (% chg)

$-0.14 (-4.98%)
Prev Close
$2.81
Open
$2.84
Day's High
$2.85
Day's Low
$2.66
Volume
4,894,942
Avg. Vol
4,776,077
52-wk High
$7.15
52-wk Low
$2.56

Chart for

About

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin... (more)

Overall

Beta: 1.29
Market Cap(Mil.): $632.12
Shares Outstanding(Mil.): 224.95
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.38 16.52
EPS (TTM): -- -- --
ROI: -- 2.39 11.32
ROE: -- 3.35 15.18

BRIEF-Synergy Pharmaceuticals secures $300 mln debt financing

* Synergy Pharmaceuticals secures $300 million debt financing

Sep 05 2017

BRIEF-Synergy Pharma Q2 sales $2.3 million

* Synergy Pharmaceuticals reports second quarter 2017 financial results and business update

Aug 09 2017

BRIEF-Synergy Pharmaceuticals reports Q1 sales $100,000

* Synergy Pharmaceuticals reports first quarter 2017 financial results and business update

May 10 2017

BRIEF-Synergy Pharmaceuticals says to present positive TRULANCE phase 3 data

* TRULANCE 3 mg,6 mg doses showed statistical significance in percent of patients who were overall responders compared to placebo Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

May 09 2017

Earnings vs. Estimates